# Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy

> **NCT05063877** · PHASE2 · UNKNOWN · sponsor: **Equilibre Biopharmaceuticals B.V.** · enrollment: 43 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Placebo
- **DRUG:** EQU-001

## Key facts

- **NCT ID:** NCT05063877
- **Lead sponsor:** Equilibre Biopharmaceuticals B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-31
- **Primary completion:** 2022-10-11
- **Final completion:** 2023-10-11
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05063877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05063877, "Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05063877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*